Y-MABS THERAPEUTICS INC (YMAB)

Y-mAbs Therapeutics Becomes Oversold (YMAB)

YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024

YMAB stock results show that Y-mAbs Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Y-mAbs Therapeutics (NASDAQ:YMAB) just reported results for the first quarter o...

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET...

Y-mAbs to Present at 2024 ASCO Annual Meeting

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development...

Y-mAbs up 17% after hours on strong 2024 guidance, quarterly beats (NASDAQ:YMAB)

Shares of Y-mAbs Therapeutics (YMAB) surge ~17% in after-hours trading following strong 2024 guidance and Q4 2023 results beating expectations. Read more here.

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively Cash and...

Notable earnings after Thursday's close

Major earnings expected after the bell on Thursday include:Zscaler (ZS)Hewlett Packard Enterprise Company (HPE)Dell Technologies (DELL)Autodesk (ADSK)Veeva...

Beam Therapeutics Stock Shows Healthy Relative Strength Improvement

In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its...

Commit To Buy Y-mAbs Therapeutics At $7.50, Earn 15.5% Annualized Using Options

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...

Y-mAbs stock gains after insider purchases (NASDAQ:YMAB)

Y-mAbs Therapeutics (YMAB) stock rises as company director Johan Wedell-Wedellsborg discloses insider purchases. Read more here.

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its...

Y-mAbs Therapeutics appoints Michael Rossi as chief executive (NASDAQ:YMAB)

Y-mAbs Therapeutics appoints Michael Rossi as President and CEO, succeeding Thomas Gad.

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...

FDA clears Y-mAbs to begin Phase 1 testing for CD38-SDA in NHL (YMAB)

Y-mAbs Therapeutics receives FDA clearance for Phase 1 testing of CD38-SADA, a radioimmunotherapy candidate for non-Hodgkin lymphoma. Read more here.

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform...

Y-mAbs Announces Publication in Cancers

Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment...

Bullish Two Hundred Day Moving Average Cross - YMAB

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of...

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the

Y-mAbs to Participate at Upcoming Investor Conferences in September

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical...